Free Trial

Universe Pharmaceuticals (UPC) Competitors

Universe Pharmaceuticals logo
$3.96 -0.06 (-1.49%)
Closing price 03:58 PM Eastern
Extended Trading
$3.90 -0.06 (-1.64%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UPC vs. VRPX, VIRX, NCNA, VINC, CAPS, BON, MYMD, SMFL, SCPS, and VAXX

Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Virpax Pharmaceuticals (VRPX), Viracta Therapeutics (VIRX), NuCana (NCNA), Vincerx Pharma (VINC), Capstone Therapeutics (CAPS), Bon Natural Life (BON), MyMD Pharmaceuticals (MYMD), Smart for Life (SMFL), Scopus BioPharma (SCPS), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.

Universe Pharmaceuticals vs. Its Competitors

Universe Pharmaceuticals (NYSE:UPC) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Universe Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Universe Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
Virpax Pharmaceuticals Neutral

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Universe Pharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$19.29M0.01-$6.16MN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Universe Pharmaceuticals beats Virpax Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

MetricUniverse PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$170K$782.13M$5.59B$20.78B
Dividend YieldN/A4.84%4.71%3.60%
P/E RatioN/A1.3627.9627.72
Price / Sales0.0124.78389.5467.40
Price / CashN/A19.5636.3223.29
Price / Book0.026.688.374.52
Net Income-$6.16M-$4.52M$3.25B$993.24M
7 Day Performance3.39%-1.96%-2.50%-2.56%
1 Month Performance5.60%5.23%7.98%2.01%
1 Year Performance-99.82%12.18%34.65%8.22%

Universe Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPC
Universe Pharmaceuticals
N/A$3.96
-1.5%
N/A-99.8%$170K$19.29M0.00220Gap Down
VRPX
Virpax Pharmaceuticals
N/A$0.33
-17.5%
N/A-99.8%$410KN/A0.007Gap Down
VIRX
Viracta Therapeutics
1.9893 of 5 stars
$0.01
flat
$1.75
+17,793.7%
N/A$389KN/A-0.0120News Coverage
NCNA
NuCana
3.2891 of 5 stars
$0.05
+6.9%
$25.00
+48,919.6%
-98.6%$290KN/A-0.0130Gap Up
High Trading Volume
VINC
Vincerx Pharma
2.6367 of 5 stars
$0.05
+9.5%
$40.00
+80,708.1%
-99.7%$259KN/A0.0060Gap Up
CAPS
Capstone Therapeutics
N/A$1.62
flat
N/AN/A$255K$43.42M0.0038News Coverage
BON
Bon Natural Life
0.5362 of 5 stars
$1.42
+0.7%
N/AN/A$240K$23.84M0.00100Gap Up
MYMD
MyMD Pharmaceuticals
N/A$0.09
-7.6%
N/A-93.9%$207KN/A0.006Gap Down
High Trading Volume
SMFL
Smart for Life
N/A$0.02
+1.9%
N/A-99.9%$150K$11.11M0.00110
SCPS
Scopus BioPharma
N/A$0.00
flat
N/AN/A$13KN/A0.009
VAXX
Vaxxinity
N/A$0.00
flat
N/A-60.0%$13KN/A0.0090Gap Up

Related Companies and Tools


This page (NYSE:UPC) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners